BoD & SCAP LOGIN

CME Policy on Full Disclosure

The Alberta Psychiatric Association requires disclosure of the existence of ANY AND ALL financial interest(s) or other affiliation(s) a presenter has with commercial supporter(s) of these educational activities, and/or with manufacturer(s) of ANY AND ALL commercial product(s) and/or provider(s) of ANY AND ALL commercial services discussed in the scientific program. The existence of such relationships does not necessarily constitute a conflict of interest, but the prospective audience must be informed of the presenter’s affiliation with every commercial sponsor by way of an acknowledgement in program.

This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own opinions about the presentation. A reasonable test to guide decisions about what to disclose is whether any particular affiliation could cause embarrassment to the individual or institution involved or lead to questions about the presenter’s motives if such affiliation(s) were made known to the general public.

The following presenters have indicated a financial interest or other affiliation with a commercial supporter of the session and/or with the manufacturer(s) of a commercial product and/or provider of commercial service(s):

Speaker Co-Author Affiliation
Nia Abdullayeva N/A

N/A

Sean Andrea Megan Puckering

N/A

David Attwood  

Served as a speaker and consultant for the following companies; AA pharma, HLS Therapeutics, Otsuka, Lundbeck, Abbvie, Boehringer

Prajjita Bardoloi N/A

N/A

Simon Baron-Cohen N/A

N/A

Janet Caryk Novjyot (Joti) Brar-Josan

N/A

Kaitlyn Chappell, Laura Stovel, and Diana Meakins Melanie Marsh-Joyal, Allison Bihari, Karen Kroeker

Allison Bihari - Co-Primary Investigator for a Digestive Health Strategic Clinical Network Grant, Alberta Health Services

Kaitlyn Chappell - Co-Investigator: Mindfulness-Based Stress Reduction (MBSR) for Adults with Inflammatory Bowel Disease (MIND-IBD, UofA Study ID: Pro00108955)
Co-Primary Investigator for a Quality Improvement Grant, “Addressing the Needs of with Mental Health Issues and Inflammatory Bowel Disease”, Pfizer Canada

Karen Kroeker - Mentoring in IBD, Steering Committee Member Crohn’s and Colitis Canada PACE Steering Committee, Co-Lead Royal College Gastroenterology Specialty Committee, Vice Chair. Co-Primary Investigator for a Quality Improvement Grant, “Addressing the Needs of with Mental Health Issues and Inflammatory Bowel Disease”, Pfizer Canada Co-Primary Investigator for a Digestive Health Strategic Clinical Network
Grant, Alberta Health Services.

Diana Meakins - Physician Member, Alberta Medical Association (AMA) Healthy Working
Environments Advisory Committee (HWEAC), 2023-present
Physician Member, Alberta Medical Association (AMA) Physician and Family
Support Program (PFSP) Advisory Committee, 2023-present
Physician Member, Alberta Health Services (AHS) Bilateral Complaints
Resolution Implementation Teams: Resource Development and Evaluation
Team, 2023-present, Physician Co-Facilitator, Alberta Health Services (AHS) Physician Leaders’ Healing Group, AHS ACMO (Physician Wellness, Diversity and Development)
Portfolio, Biweekly Apr-Jun, 2022. Honoraria from the Alberta Medical Association (AMA) for Healthy Working Environments Advisory Committee (HWEAC) and Family Support Program (PFSP) Advisory Committee attendance Stipend from Alberta Health Services (AHS) for Bilateral Complaints Resolution Implementation Teams: Resource Development and Evaluation Team Meeting attendance Payment from Alberta Health Services (AHS) for Physician Leaders’ Healing Group, AHS ACMO (Physician Wellness, Diversity and Development) Portfolio, Biweekly Apr-Jun, 2022

Melanie Marsh-Joyal - Alberta Health Services (AHS) for AHS Zone Clinical Department Facility Chief (ZCDFC), Adult Psychiatry, Royal Alexandra Hospital (RAH), 2023-present. Payment from Alberta Health Services (AHS) for AHS Zone Clinical Department Facility Chief (ZCDFC), Adult Psychiatry, Royal Alexandra Hospital (RAH)

Laura Stovel - Psychiatrist Member, Alberta Mental Health Review Panel, North Sector, 2020-present, Psychiatrist Member, Criminal Code Review Board, 2021-present
Contributor, Royal College of Physicians and Surgeons of Canada (Psychiatry Specialty Committee, Examination Board in Psychiatry, Residency Accreditation Survey Teams). Member of the Royal College of Physicians and Surgeons Examination Board in Psychiatry. Payments from the Alberta Mental Health Review Panel and the Alberta Criminal Code Review Board for participation in hearings

Kaitlin Chivers-Wilson
Thomas Stark
Thomas Stark
Erin Talbot
Christina Volstad
Evelyne Felber Charbonneau

Kaitlyn Chivers - Practise Supports and Provincial Partnerships Accreditation Committee; Newly Institute Scientific Advisory Board. Research support from Veterans Affairs Canada and Calgary Health Trust. Speaker honoraria from Abbvie.

Thomas Stark - HLS Therapeutics, Otsuka, EISIA - Fees for Educational Talks and receipt of honoraria

Erin Talbot - Employee of Carwest Operational Stress Injury Clinic.

Pratap R. Chokka & Toba Oluboka

 

Pratap R. Chokka - Abbvie, Lundbeck, Janssen, Takeda, Otsuka

Toba Oluboka - Janssen Canda, Otsuka Canada, Lundbeck Canada, VIATRIS, Eisai, Pfizer Pharmaceutical,HLS Therapeutics, Abbvie, Allergan, Otsuka-Lundbeck Alliance

Janet de Groot & Elizabeth Wallace  

Janet de Groot - Alberta Cancer Foundation Grant 2020-20232. Cumming School of Medicine, OHMES-EDI grant 2023-20253. Carol May Yates Memorial Endowment Grant for Cancer Research 2023-2024

Shaista Goel Maryana Kravtsenyuk

N/A

Payman Hajiazim N/A

Lectures before for the physicians while supported by Novartis, Abbvie, Eisai, Paladin

Abbvie, Eisai, Flamel, Idorsia, Novartis, Paladin, Sunovion, 

Tyler Halverson Joao Morgadinho, Kannayiram Alagiakrishnan

 

Steve Hyman N/A

Director, Voyager Therapeutics
Director, Vesalius Therapeutics
Director, Cyclerion Therapeutics
Director, Wyss Center (Geneva) nonprofit

Scientific Advisory Board J&J
Scientific Advisory Board F-Prime Capital

Maryana Kravtsenyuk N/A

N/A

John Krystal N/A

Stock from Biohaven Pharmaceuticals and Spring Care, Inc.

Stock Options from Biohaven Pharmaceuticals Medical SciencesClearmind Medicine, Inc. EpiVario, Inc.Neumora Therapeutics, Inc. Tempero Bio, Inc.Terran Biosciences, Inc.Tetricus, Inc.

Editorial Board - Editor - Biological Psychiatry

Freedom Biosciences, Inc. – Science Advisory Board

Patents include:

  1. Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent #:5,447,948.September 5, 1995
  2. Vladimir, Coric, Krystal, John H, Sanacora, Gerard – Glutamate Modulating Agents in the Treatment of Mental Disorders. US Patent No. 8,778,979 B2 Patent Issue Date: July 15, 2014. US Patent Application No. 15/695,164: Filing Date: 09/05/2017
  3. Charney D, Krystal JH, Manji H, Matthew S, Zarate C., - Intranasal Administration of Ketamine to Treat Depression United States Patent Number: 9592207, Issue date: 3/14/2017. Licensed to Janssen Research & Development
  4. Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Yale University “Methods for Treating Suicidal Ideation”, Patent Application No. 15/379,013 filed on December 14, 2016 by Yale University Office of Cooperative Research
  5. Arias A, Petrakis I, Krystal JH. – Composition and methods to treat addiction. Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research.
  6. Chekroud, A., Gueorguieva, R., & Krystal, JH. “Treatment Selection for Major Depressive Disorder” [filing date 3rd June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by Yale University
  7. Gihyun, Yoon, Petrakis I, Krystal JH – Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. U. S. Provisional Patent Application No. 62/444,552, filed on January10, 2017 by Yale University Office of Cooperative Research OCR 7088 US01
  8. Abdallah, C, Krystal, JH, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. U.S. Provisional Patent Application No. 62/719,935 filed on August 20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01
  9. John Krystal, Godfrey Pearlson, Stephanie O’Malley, Marc Potenza, Fabrizio Gasparini, Baltazar Gomez-Mancilla, Vincent Malaterre. Mavoglurant in treating gambling and gaming disorders. U.S. Provisional Patent Application No. 63/125,181filed on December 14, 2020 by Yale University Office of Cooperative Research OCR 8065 US00

Funded grants or clinical trials include:

NON Federal Research Support

AstraZeneca Pharmaceuticals provides the drug, Saracatinib, for research related to NIAAA grant “Center for Translational Neuroscience of Alcoholism [CTNA-4]

Novartis provides the drug, Mavoglurant, for research related to NIAAA grant “Center for Translational Neuroscience of Alcoholism [CTNA-5]

Cerevel provides the drug PF-06412562 for A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for Schizophrenia (5 U01 MH121766-03)

Membership on advisory boards or speakers' bureaus include AE Research Foundation Advisory BoardBiogen, Idec, MABiohaven PharmaceuticalsBioXcel Therapeutics, Inc. (Clinical Advisory Board)Cerevel Therapeutics, LLCDelix Therapeutics, Inc.Eisai, Inc.EpiVario, Inc.Freedom Biosciences, Inc.Jazz Pharmaceuticals, Inc.Neumora Therapeutics, Inc. Neurocrine Biosciences, Inc.Novartis Pharmaceuticals CorporationPerception Neuroscience, Inc. Praxis Precision Medicines, Inc.PsychoGenics, Inc.Takeda IndustriesTempero Bio, Inc.Terran Biosciences, Inc.Tetricus, Inc.

Financial payments include Consultant for:Aptinyx, Inc.Biogen, Idec, MABionomics, Limited (Australia)BioXcel TherapeuticsBoehringer Ingelheim InternationalCerevel Therapeutics, LLCClearmind Medicine, Inc.Cybin IRL (Ireland Limited Company)Enveric BiosciencesEpiodyne, Inc. EpiVario, Inc.Evidera, Inc.Janssen Research & DevelopmentJazz Pharmaceuticals, Inc.Leal Therapeutics, Inc.Otsuka America Pharmaceutical, Inc.Perception Neuroscience, Inc. Praxis Precision Medicines, Inc.Spring Care, Inc.Sunovion Pharmaceuticals, Inc.Tetricus, Inc.

Usama Malik

Jennifer Swainson, Matthew Reeson, Ian Stefanuk, Mary Cummins, Sudhakar Sivapalan

 

Alexandra McPherson N/A

CAMAP (Board Member), Honoraria from Health Canada

Hassan Nawab Morgan Glass, Thomas Raedler

Morgan Glass - University of Toronto

Thomas Raedler - Abbvie / Allergan, AMHSP of the University of Calgary, Boehringer / Ingelheim, HLS, Newron, Otsuka, Sunovion, SyneuRx International, TEVA

Rachael Nicholls Davide Martino, Tamara Pringsheim, Natalia Szejko

Tamara Pringsheim - CIHR

Davide Martino - Merz Pharmaceuticals - Abbvie, 

Natalia Szejko - American Academy of Neurology, American Brain Foundation, Biogen, Polish Ministry of Health, Tourette Association of America

Abhinav Pillai Tan Li, Sharon Parappally-Joseph,
Martin Vetter

Martin Vetter - Elvium advisory board, Elvium speaker fee

Catherine Phillips and Linda Crockett N/A

Canadian institute of Workplace Bullying Resources- Founder- Linda Crockett

Canadian Institute of Workplace Violence and Harassment- Founder - Linda Crockett

Board member- Catherine Philips

Thomas Joseph Raedler N/A

Abbvie / Allergan, AMHSP of the University of Calgary, Boehringer / Ingelheim, HLS, Newron, Otsuka, Sunovion, SyneuRx International, TEVA

Roger Rampling N/A

N/A

Hasina Samji N/A

BC Centre for Disease Control, CIHR, Simon Fraser  University and SSHRC. 

Dallas Seitz N/A

Canadian Institutes of Health Research, University Health Foundation - Alberta Roche Collaboration in Health, Alzheimer Association, Calgary Health Foundation, Public Health Agency of Canada

Stipend from Alberta Health Services for Scientific Director of PAMH.

Rory Sellmer and Monique Jericho N/A

Monique Jericho - Silver Linings Foundation, Lionheart Foundation, Clinical consultation support with accessing grants

Rory Sellmer - Ad boards for Otsuka, Abbvie, and HLS therapeutics. Speaker fees for Abbvie.

Norma Shipley N/A

Alberta Medical Association

Thomas Stark Martin Vetter

Thomas Stark - HLS Therapeutics, Otsuka, EISIA - Fees for Educational Talks and receipt of honoraria

Martin Vetter - Elvium advisory board, Elvium speaker fee

John Strang N/A

Action on Addiction, Addictions CAG (Clinical Academic Group), Clouds (Action on Addiction), DrugFAM, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), FDA (US Food and Drug Administration), Institute of Psychiatry, Psychology and Neuroscience, KCA (Kent Council on Addictions), Kings College London, King’s Health Partners Academic Health Sciences Centre, Lifeline (Manchester), NIDA (US National Institute on Drug Abuse), Phoenix House, Scottish Drug Forum (SDF), Scottish Families affected by Alcohol and Drigs (SFAD), South London & Maudsley (SLaM) NHS Foundation Trust, UK Drug Policy Commission (UKDPC),  United Nations Office on Drugs and Crime (UNODC) and World Health Organization (WHO).4

Grant support/honoraria/consultancy payments from Accord/Molenti, Camurus, Department of Health, EMCDDA (European Monitoring Centre for Drugs and Drug Addiction), Home Office, NICE (National Institute for Health and Clinical Excellence), NIHR (National Institute on Health Research), NTA (National Treatment Agency), MRC (Medical Research Council), MundiPharma, PHE (Public Health England), Pilgrim Trust, SME Pneumowave, SHIP/OLS/SBRI, Societyy for the Study of Addcition (SSA) and Q2i/CMI.

Gustavo Turecki N/A N/A
Bohan Yang Marnie MacKay, Serdar M. Dursun, Glen B. Baker Glen B. Baker - Member of SAB, but gave advice on basic science studies on MAO inhibitors that has no relationship to Bohan’s presentation. I stepped down from the SAB in April, 2023. Received $1,000 USD per month, which stopped after April, 2023.
Verna Yiu N/A N/A